

## ASX Announcement

October 17, 2019

---

### Change of Director's Interest – Appendix 3Y

**Sydney, Australia | October 11, 2019** – Multi-award-winning Australian technology company Calix Limited (ASX:CXL) advises that Founder, Chief Scientist and Executive Director, Dr Mark Sceats has exercised \$231,000 of unlisted warrants. The warrants have been converted into fully paid shares that are subject to escrow until July 2020.

Appendix 3Y is attached.



## For more information:

Phil Hodgson  
**Managing Director and CEO**  
phodgson@calix.com.au  
+61 2 8199 7400

Simon Hinsley  
**Investor Relations**  
simon@nwrcommunications.com.au  
+61 401 809 653

Darren Charles  
**Company Secretary and CFO**  
dcharles@calix.com.au  
+61 2 8199 7400

Michelle Taylor  
**Media**  
Michelle\_Taylor@recognition.com.au  
+61 2 9252 2266

## About Calix

Calix is a team of dedicated people developing a unique, patented technology to provide industrial solutions that address global sustainability challenges.

The core technology is being used to develop more environmentally friendly solutions for advanced batteries, crop protection, aquaculture, wastewater, and carbon reduction.

Calix develops its technology via a global network of research and development collaborations, including governments, research institutes and universities, some of world's largest companies, and a growing customer base and distributor network for its commercialised products and processes.

Because there's only one Earth – Mars is for Quitters.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity – Calix Limited</b>
<b>ABN – 36 117 372 540</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr. Mark Geoffrey Sceats
<b>Date of last notice</b>	9 April 2019

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	16/10/2019
<b>No. of securities held prior to change</b>  <b>Direct</b> Mark Geoffrey Sceats  <b>Indirect</b> Mark Geoffrey Sceats <Sceats Superannuation Fund> (Trustee & beneficiary)  Elizabeth Elenius (Spouse)  Adam Vincent & Sina Kassra <Employee Share Scheme A/C> (Beneficiary)	  2,965,050 Ordinary shares 766,357 Performance rights  2,759,736 Ordinary shares 412,500 Unlisted Warrants  305,466 Ordinary shares 49,500 Unlisted Warrants  1,312,196 Ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class</b>	Fully Paid Ordinary Shares escrowed until July 2020.
<b>Number acquired</b>	462,000
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$231,000
<b>No. of securities held after change</b>  Mark Geoffrey Sceats <Sceats Superannuation Fund> (Trustee & beneficiary)  Elizabeth Elenius (Spouse)  Adam Vincent & Sina Kassra <Employee Share Scheme A/C> (Beneficiary)  Mark Geoffrey Sceats	 3,172,236 Ordinary shares [includes 2,421,052 escrowed until July 2020]  354,966 Ordinary shares [includes 261,050 escrowed until July 2020]  1,312,196 Ordinary shares  2,965,050 Ordinary shares [includes 2,322,126 escrowed until July 2020] 766,357 Performance rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of escrowed warrants expiring on 31 October 2019 in to fully paid ordinary shares escrowed until July 2020

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
<b>Interest after change</b>	-

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	-
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	-
<b>If prior written clearance was provided, on what date was this provided?</b>	-

---

<sup>+</sup> See chapter 19 for defined terms.